• No results found

Applying the Principles of Antiemetic Therapy to the Management of CINV: A Case-study Approach

N/A
N/A
Protected

Academic year: 2021

Share "Applying the Principles of Antiemetic Therapy to the Management of CINV: A Case-study Approach"

Copied!
21
0
0

Loading.... (view fulltext now)

Full text

(1)

Applying the Principles of

Antiemetic Therapy to the

Management of CINV:

A Case-study Approach

(2)

Applying the Principles of Antiemetic Therapy to the Management

of CINV: A Case-study Approach

Program Agenda

6:15 a.m. – 6:45 a.m. Registration and Breakfast Buffet

6:45 a.m. – 6:50 a.m. Introductory Remarks

Rowena N. Schwartz, Pharm.D., BCOP, Program Moderator

6:50 a.m. – 7:15 a.m. Expensive New Antiemetics for Cancer Patients: Where Do They Belong in Therapy?

Val R. Adams, Pharm.D., FCCP, BCOP

7:15 a.m. – 7:40 a.m. Case Studies: Management of CINV in the Patient with Cancer

Rowena N. Schwartz, Pharm.D., BCOP Val R. Adams, Pharm.D., FCCP, BCOP 7:40 a.m. – 7:45 a.m. Question and Answer Discussion

Program Faculty

Rowena N. Schwartz, Pharm.D., BCOP, Program Moderator

Associate Professor, Pharmacy and Therapeutics School of Pharmacy

University of Pittsburgh Pittsburgh, Pennsylvania

Val R. Adams, Pharm.D., FCCP, BCOP

Associate Professor, Pharmacy Practice and Science College of Pharmacy

University of Kentucky

Lucille P. Markey Cancer Center Lexington, Kentucky

(3)

Applying the Principles of Antiemetic Therapy to the Management

of CINV: A Case-study Approach

Program Description

Chemotherapy-induced nausea and vomiting (CINV) is a common and dreaded side effect of cancer chemotherapy that adversely affects quality of life and may deter patients from

completing the recommended chemotherapy. Despite the development of increasingly effective antiemetic therapies and the availability of authoritative guidelines for their use, the prevalence and impact of CINV remains a concern. Risk factors for CINV include the emetogenic potential of the specific chemotherapeutic agent and individual patient

characteristics. Patients receiving multi-day chemotherapy regimens are at risk for both acute CINV (that which occurs within several hours after chemotherapy administration and resolves within 24 hours) and delayed CINV (that which begins more than 24 hours after chemotherapy administration and lasts for days). In addition, recent research concerning the pathophysiology of acute versus delayed CINV underscores the need for a different approach to the treatment of each condition and evidence demonstrating that delayed CINV is more prevalent than

previously thought requires increased vigilance on the part of health-care practitioners. This program will explore considerations in selecting among the available antiemetic agents, including the type, dose, and schedule of chemotherapy (i.e., emetogenic potential); type of CINV (i.e., acute vs. delayed); outcome of previous antiemetic therapy; anticipated adverse effects; the frequency and severity of CINV; and patient characteristics and preference.

Learning Objectives

At the conclusion of this program, participants should be able to:

• Identify the neurotransmitters and explain the pathophysiologic mechanisms involved in CINV.

• Explain the mechanisms of action of the various antiemetic agents used to manage acute and delayed CINV.

• Discuss the basic principles of antiemetic therapy to prevent and treat acute, delayed, anticipatory, breakthrough, and refractory CINV as they apply to specific patient cases.

• Recommend antiemetic therapy for a specific patient receiving a moderately emetogenic cancer chemotherapy regimen.

• Recommend antiemetic therapy for a specific patient receiving a highly emetogenic cancer chemotherapy regimen.

Continuing Education Accreditation

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program provides 1 hour (0.1 CEU) of continuing education credit (program number 204-000-05-475-L01). Attendees must complete a Continuing Pharmacy Education Request online and may immediately print their official ASHP CE statements at the ASHP Advantage CE Processing Center at

(4)

Applying the Principles of Antiemetic Therapy to the Management

of CINV: A Case-study Approach

Rowena N. Schwartz, Pharm.D., BCOP

Associate Professor, Pharmacy and Therapeutics School of Pharmacy

University of Pittsburgh Pittsburgh, Pennsylvania

Dr. Rowena Schwartz is Associate Professor and Vice Chair of Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy and Coordinator, Pharmacy Programs at the University of Pittsburgh Cancer Institute (UPCI). In addition, Dr. Schwartz developed and currently directs the UPCI Cancer Pain Program and maintains an active clinical pharmacy practice at UPCI in the medical oncology, hematology, and bone marrow transplant adult inpatient care units.

Dr. Schwartz received a Bachelor of Science in Pharmacy degree from the College of

Pharmacy, University of Illinois at the Medical Center in Chicago and her Doctor of Pharmacy at the University of Texas Health Science Center at San Antonio. She completed a two-year fellowship in oncology drug development at the University of Texas. Dr. Schwartz is a board-certified oncology pharmacist.

Dr. Schwartz’s research interest is in the use of novel drug therapy in the management of cancer and cancer-related complications with a focused interest in geriatric oncology. She is a an active member of the American Society of Health-System Pharmacists, the Pennsylvania Society of Health-System Pharmacists, the American Association of Colleges of Pharmacy, the American College of Clinical Pharmacy, the Pennsylvania Cancer Pain Initiative, the

Hematology and Oncology Pharmacy Association, the Geriatric Oncology Consortium, and the International Society of Oncology Pharmacy. In addition, Dr. Schwartz is a member of the Specialty Council on Oncology Pharmacy for the Board of Pharmaceutical Specialties. She has authored numerous book chapters, journal articles, and abstracts on various topics related to pharmacy practice in oncology.

(5)

Applying the Principles of Antiemetic Therapy to the Management

of CINV: A Case-study Approach

Val R. Adams, Pharm.D.,

FCCP, BCOP

Associate Professor, Pharmacy Practice and Science College of Pharmacy

University of Kentucky

Lucille P. Markey Cancer Center Lexington, Kentucky

Dr. Val Adams is Associate Professor in the Division of Pharmacy Practice and Science in the College of Pharmacy at the University of Kentucky. He is part of the graduate faculty and staff member at the Markey Cancer Center, where he has a clinical practice site. As the director of the hematology/oncology residency program, Dr. Adams has trained twelve residents and maintains an active research lab. He received his B.S. degree in pharmacy from the University of Utah and received his Pharm.D. degree from the University of Texas at Austin jointly with the University of Texas Health Science Center at San Antonio. He completed a residency in

hematology/oncology at the Audie L. Murphy Memorial V.A. Hospital in San Antonio, Texas and then completed a two-year fellowship in immunology and transplantation at the University of Florida. Following the completion of the fellowship, he joined the University of Kentucky faculty in 1996.

(6)

Applying the Principles of

Antiemetic Therapy to the

Management of CINV: A Case-study

Approach

40th ASHP Midyear Clinical Meeting Las Vegas, Nevada

Expensive New Antiemetics

for Cancer Patients:

Where

Do They Belong in Therapy?

Val R. Adams, Pharm.D., FCCP, BCOP Associate Professor, Pharmacy Practice and Science

University of Kentucky Lucille P. Markey Cancer Center

Lexington, Kentucky

Objectives

At the conclusion of this program, participants should be able to:

‹Define the current CINV problems. ‹Describe the pathophysiology of CINV. ‹Recommend CINV preventive treatment based

(7)

CINV Rates

N = 322 Pts Assessed 245 (76%) Nausea (N) 139 (43%) Acute N 126 (39%) Acute & Delayed N 234 (73%) Delayed N 96 (30%) Vomiting (V) 36 (11%) Acute V 21 (7%) Acute & Delayed V 81 (25%) Delayed V

Hickok JT, et al. Cancer. 2003;97:2880-6.

Cycle 1

Palonosetron Trial HEC

Time (h) 10 20 0 30 40 50 60 70 80 90 100 0 24 48 72 96 120 P er ce n t o f P at ie n ts Palonosetron 0.25 mg (n=223) Palonosetron 0.75 mg (n=223) Ondansetron 32 mg (n=221)

P=NS for palonosetron 0.25 mg or 0.75 mg vs ondansetron

Time to treatment failure = time to 1stemetic episode or use of rescue medication

PALO-99-05 HEC

Time (h)

Palonosetron Trial MEC

P er ce n t o f P at ie n ts 10 20 0 30 40 50 60 70 80 90 100 0 24 48 72 96 120 Palonosetron 0.25 mg (n=189) Palonosetron 0.75 mg (n=189) Dolasetron 100 mg (n=191)

*P=0.017 for palonosetron 0.25 mg vs dolasetron

P=0.025 for palonosetron 0.75 mg vs dolasetron

*

Time to treatment failure = time to 1stemetic episode or use of rescue medication

(8)

Is CINV Still A Problem?

Types of Nausea and Vomiting

Anticipatory Acute Delayed

Time Chemo 24 hours

Anticipatory

‹Pathophysiology

– Learned response from prior therapy

‹Treatment

– Best therapy is prevention of emesis during chemotherapy

– Relaxation techniques shown to be effective – Benzodiazepines

™Lorazepam usually beginning prior to

(9)

Acute

GI Tract 5-HT3, NK1 CTZ D2, 5-HT3, NK1, M Cortex NTS D2, H1, 5-HT3, NK1, M VOMITING CENTER Salivatory Center Respiratory Center Vasomotor Center Cranial Nerves Effector Organs

CTZ = chemoreceptor trigger zone, NTS = nucleus tractus solitarious Receptor abrev. D2 = dopamine 2 , 5-HT3 = serotonin 3, M = muscarinic H1 = histamine 1, NK1 = neurokinin 1

Serotonin and Chemotherapy

0 2 4 6 8 10 12 14 16 0 5 10 15 20 25 30 Cyclophosphamide Cisplatin Urinary

5HIAA (note estim

ated

va

lue

s)

Hours after Chemotherapy Administration

Cubeddu LX. Oncology.1996;53(suppl 1):18-25.

Patterns of Acute Emesis

0 10 20 30 40 50 60 70 80 90 100 2 4 6 8 10 12 14 16 18 20 22 24 Cisplatin Carboplatin % of pts w / v om iting during prior 2 hrs Time (hours)

(10)

5HT3 RA vs NK1 RA Response

Time to First Emesis or Rescue

Ond Apr

Aprepitant Study #004. Cocquyt V, et al. Eur J Cancer.2001;37:835.

Delayed Nausea and Vomiting

‹Pathophysiology unknown ‹Pathologic findings

– Altered GI motility

– Normal levels of serotonin metabolites in the urine

– Involves NK1 receptor stimulation in the CNS – Nausea and vomiting in acute phase increases

risk

‹Chemotherapy implicated: cisplatin, carboplatin,

cyclophosphamide

Acute CINV Linked to Delayed CINV

No Acute CINV No Delayed 76% Yes Delayed 24% Yes Acute CINV No Delayed 20% Yes Delayed 80%

(11)

Changing Beliefs

‹CINV is still a problem, even with MEC

‹Serotonin in the first 8 hours

‹Substance P during 8–120 hours

‹Traditional definition of acute and delayed

does not match the physiology

MEC = moderately emetogenic chemotherapy

Prevention of CINV: Risk Factors

‹Guideline considerations

– Drug(s), dose(s), and rate of administration – Prior N/V with chemotherapy

‹Other high-risk factors not incorporated in

guidelines:

– Young age, female, no alcohol history,

concurrent radiation, history of N/V with pregnancy or motion sickness

Emetogenicity of Chemotherapy

‹Based on percent of patients that will get

sick if given no antiemetic

Level 1 (low) < 10% Level 2 (moderately low) 10 - 30% Level 3 (moderate) 30 - 60% Level 4 (moderately high) 60 - 90% Level 5 (highly) > 90%

(12)

NCCN CINV Guideline

High (Level 5)

STARTING PRIOR TO CHEMOTHERAPY

1. Aprepitant 125 mg po d1, 80 mg po d2&3

2. Dex 12 mg po/iv d1, 8 mg po/iv d2-4 3. 5HT3 RA po/iv d1

+/- Lorazepam 0.5 – 2 mg po/iv/subling q6h d1-4

National Comprehensive Cancer Network (NCCN). Antiemesis Guideline, v.1.2005.

NCCN CINV Guideline

Day 1 1. Dexamethasone 2. 5HT3 RA +/- Lorazepam +/- Aprepitant * *carboplatin, cyclophosphamide, doxorubicin, epirubicin, ifosfamide, irinotecan, or

methotrexate Moderate (Level 3–4)

Day 2-4

1a. Dexamethasone or 1b. 5HT3 RA or 1c. Metoclopramide or 1d. Aprepitant & dex ** +/- Lorazepam

**Only if aprepitant used on d1

NCCN. Antiemesis Guideline, v.1.2005.

NCCN CINV Guideline

Low (Level 2) 1a. Dexamethasone or 1b. Prochlorperazine or 1c. Metoclopramide* +/- Lorazepam *Consider adding diphenhydramine Minimal (Level 1) No Routine Prophylaxis NCCN. Antiemesis Guideline, v.1.2005.

(13)

Assessing Response

‹Primary Endpoint:

Complete Response= no emesis and no

rescue medication

‹Secondary Endpoints:

– Frequency of vomiting episodes – Use of rescue therapy

– Nausea

– Quality of life (FLIE)

FLIE = functional living index emesis questionnaire

Case Studies:

Management of CINV

in the Patient with Cancer

Rowena N. Schwartz, Pharm.D., BCOP

Associate Professor, Pharmacy and Therapeutics School of Pharmacy

University of Pittsburgh Pittsburgh, Pennsylvania

and

Val R. Adams, Pharm.D., FCCP, BCOP

Associate Professor, Pharmacy Practice and Science University of Kentucky

Lucille P. Markey Cancer Center Lexington, Kentucky

Case: Management of CINV in the Patient with Cancer

JS is a 79-year-old male with NHL

History of Present Illness:

ƒ 2 months ago JS c/o SOB and cough ƒ s/p antibiotics without change in symptoms ƒ CXR: RUL mass ⇒biopsy c/w NHL (DLBCL) ƒ s/p CHOP-R x 1

ƒ Planned treatment: CHOP-R X 6 – 8

c/o = complaint of; SOB = shortness of breath; CXR = chest x-ray; RUL = right unilateral; c/w = consistent with; NHL = non-Hodgkin’s lymphoma; DLBCL = diffuse large B-cell lymphoma; CHOP-R = cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone, plus rituximab

(14)

Case: Management of CINV in the Patient with Cancer

JS is a 79-year-old male with NHL(cont’d)

Past Medical History:

ƒ Hypertension x 20 years (tx: benazepril 10 mg po QD)

ƒ 25 pack-year smoking history

ƒ Depression (tx: paroxetine 20 mg po QD)

Laboratory results:

ƒ CBC WNL

ƒ Electrolytes WNL

ƒ Liver function test WNL

ƒ Increased creatinine from baseline

ƒSCr 2 weeks ago: 1.1 mg/dl

ƒCurrent SCr: 1.8 mg/dl

ƒ ⇑Glucose 190 mg/dl; HgAICpending

Case: Management of CINV in the Patient with Cancer

JS is a 79-year-old male with NHL (cont’d) Presentation Today:

ƒ s/p one course of chemotherapy

Pre-medication: dolasetron po

Discharge Rx for CINV: prochlorperazine prn

ƒ Patient’s wife reports that JS experienced chronic

nausea (>4 days) that was not well managed with prochlorperazine

ƒ Patient states he did not take prochlorperazine because

of sedation

ƒ Patient is concerned about ability to work during

treatment

s/p = status post

Challenges of Antiemetic Therapy: Maintaining the Individuals QOL

(15)

Case: Management of CINV in the Patient with Cancer

MP is a 42-year-old female with NHL

History of Present Illness:

ƒ MS noted a swelling in her abdomen that

progressively worsened ⇒biopsy c/w NHL (DLBCL) about 16 months ago

ƒ s/p CHOP-R x 6 with complete response

ƒ Recently MP noted a new lymph node ⇒ evaluation

demonstrated recurrent NHL

ƒ Plan chemotherapy: ESHAP x 2 prior to auto HSCT

transplantation

ESHAP = etoposide, methylprednisolone, high-dose ara-C, platinol; HSCT = hematopoietic stem cell transplant

Case: Management of CINV in the Patient with Cancer

MP is a 42-year-old female with NHL (cont’d)

Past Medical History:

ƒ Insomnia (tx: trazadone 150 mg po q hs) ƒ Recent onset of hot flashes and irregular menses

ƒ Anxiety (tx: prn lorazepam and behavorial therapy)

ƒ Nausea history:

• Significant nausea with last 2 cycles of CHOP • Nausea with pregnancy

Planned therapy:

ƒ Etoposide 60 mg/m2/day IV daily x 4

ƒ Methylprednisolone 500 mg IV daily x 5

ƒ Cisplatin 25 mg/m2/day CI daily x 4

ƒ Cytarabine 2 grams/m2IV x 1 on day 5

Case: Management of CINV in the Patient with Cancer

MP is a 42year-old female with NHL (cont’d)

Social History:

ƒ Recently divorced with 4 children (ages 10, 12,

14, 20)

ƒ Occupation: investment banker

ƒ Local support includes friends, a sister who lives

(16)

Case: Management of CINV in the Patient with Cancer

MK is a 27-year-old female s/p melanoma

History Present Illness:

ƒ MK noted a mole on her shoulder about 6

months ago ⇒when the mole bled she decided to get the mole removed; biopsy was consistent with cutaneous melanoma

ƒ MK is currently participating in a trial that is

evaluating the role of biochemotherapy as adjuvant therapy post resection

Case: Management of CINV in the Patient with Cancer

MK is a 27-year-old female s/p melanoma (cont’d)

Past Medical History:

ƒ Irritable bowel syndrome

ƒ Planned therapy:

ƒcisplatin 20 mg/m2/day IV daily x 4

ƒvinblastine 1.6 mg/m2/day IV daily x 4

ƒdacarbazine 800 mg/m2 IV day 1

ƒaldesleukin 9 million international units / m2 CI daily x 4

ƒinterferon alfa 5 million units/m2/day subcutaneously days 1, 2, 3, 4, 5 and 7, 9, 11, 13

Case: Management of CINV in the Patient with Cancer

MK is a 27-year-old female s/p melanoma (cont’d)

Social History:

ƒ Married with one child (6 months)

ƒ Occupation: works part time at office supply store and full-time college student

ƒ Insurance coverage per husband (critical care

(17)

Case: Management of CINV in the Patient with Cancer

KZ is a 71-year-old female with multiple myeloma

History Present Illness:

ƒ s/p femur fracture about 6 months ago ⇒evaluation at that

time suggestive of lytic lesions ⇒evaluation consistent with MM (IgG)

ƒ s/p thalidomide + dexamethasone ⇒d/c neuropathy and constipation

ƒ s/p DVD (doxil + vincristine + dex) x 4 cycles ƒ s/p mobilization with filgrastim

ƒ s/p HSCT 8 days ago

(preparative regimen: melphalan)

MM = metastatic melanoma

Case: Management of CINV in the Patient with Cancer

KZ is a 71-year-old female with multiple myeloma (cont’d)

Past Medical History:

ƒ Diabetes x 40 years (tx: insulin) ƒ Anxiety x 30+ years (tx: prn lorazepam)

ƒ Hypercholesterolemia (tx: statin therapy d/c at transplant) ƒ s/p DVT at time of orthopedic surgery (anticoagulation held at

this time ⇒low platelets)

ƒ Depression (tx: paroxetine 20 mg po QD)

DVT = deep vein thrombosis

Case: Management of CINV in the Patient with Cancer

KZ is a 71-year-old female with multiple myeloma(cont’d)

Presentation Today:

ƒ Nausea/vomiting x 2 weeks

• ⇑nausea 2 days post transplantation

vomiting x 4 in last 24 hours

ƒ Mucositis currently on hydromorphone PCA

ƒ Febrile within the last 24 hours current antibiotics include cefepime + fluconazole

(18)

Case: Management of CINV in the Patient with Cancer

JM is a 45-year-old female with recurrent breast cancer

History Present Illness:

ƒ Diagnosed with early stage breast cancer 4 years ago

• ER- PR – • HER2Neu + (FISH)

ƒ s/p lumpectomy + radiation

ƒ JM noted lump in her breast ⇒biopsy consistent with breast cancer

ƒ Planned treatment:

• Lumpectomy ⇒radiation ⇒chemotherapy ⇒trastuzumab

ER = estrogen receptor; PR = progesterone receptor; FISH = fluorescence in situ hybridization

Case: Management of CINV in the Patient with Cancer

JM is a 45-year-old female with recurrent breast cancer (cont’d)

Past Medical History:

ƒ Hypothyroidism (tx: Synthroid®)

Planned therapy:

ƒ Doxorubicin 60 mg/m2IV day 1

ƒ Cyclophosphamide 600 mg/m2day 1

Case: Management of CINV in the Patient with Cancer

JM is a 45-year-old female with recurrent breast cancer (cont’d)

Social History:

ƒ Single with two children (ages 10 and 14)

ƒ Occupation: self-employed owner of a chain of small

diners throughout the Midwest

ƒ Support system:

• significant other x 3 years

• extended family (including parents, 6 brothers and 2 sisters)

(19)

Questions and Discussion

We welcome your questions.

Staff will collect all written question cards.

Please approach the standing microphones in the aisle. Please complete the program evaluation and hand to staff as you exit.

Thank you for your attention. Join us again for CE in the Mornings.

(20)

Applying the Principles of Antiemetic Therapy to the Management

of CINV: A Case-study Approach

References

Cocquyt V, Van Belle S, Reinhardt RR et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer. 2001;37(7):835-42.

Cubeddu LX. Serotonin mechanisms in chemotherapy-induced emesis in cancer patients.

Oncology. 1996;53(suppl 1):18-25.

Hickok JT, Roscoe JA, Morrow GR et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer. 2003;97:2880-6.

Martin M. The severity and pattern of emesis following different cytotoxic agents. Oncology.

1996;53:26-31.

National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Antiemesis,. Vol 1.2005. Available at http://www.nccn.org/professionals/physician_gls/ PDF/antiemesis.pdf (accessed 2005, Nov).

(21)

Applying the Principles of Antiemetic Therapy to the Management

of CINV: A Case-study Approach

Faculty Disclosure Statements

ASHP Advantage requires that faculty members disclose any relationships (e.g., shareholder, recipient of research grant, consultant or member of an advisory committee) that the faculty may have with commercial companies whose products or services may be mentioned in their

presentations. The existence of these relationships is provided for the information of attendees and should not be assumed to have an adverse impact on faculty presentations. The faculty reports the following relationships:

Rowena N. Schwartz, Pharm.D., BCOP

Dr. Schwartz reports that she serves on a speakers’ bureau for Merck, MGI Pharma, and sanofi aventis and as a consultant for Merck and MGI Pharma.

Val R. Adams, Pharm.D., FCCP, BCOP

Dr. Adams reports that he serves on a speakers’ bureau for Merck and Roche.

References

Related documents

Coaches work with players to set goals, uncover performance and behavioral gaps and increase the underlying skill and knowledge required to execute as effectively

© Copyright 2015 The Sales Management Association.. All

First, the utility of implementing a DIDO optimization for the purposes of studying a fuel optimized lunar landing trajectory with respect to the current trade space of both

A loan is considered to be a HOEPA loan if either the APR exceeds the rate of a comparable Treasury security by more than 8 percentage points on a first mortgage, 10 percentage

CHAPTER III: The effect of electrospray method of encapsulation on the viability of living cells within alginate based microcapsules

Keywords: Lantau Island, Hong Kong, geographic information system, GIS, deliberation, social choice theory.. Acknowledgement: We would like to acknowledge the University of

The setting up of NCLT was made possible by a Supreme Court order in May 2010 which affirmed Parliament’s power to create such a tribunal which would subsume